Home > Journals > Journal of Radiological Review > Past Issues > Journal of Radiological Review 2022 September;9(3) > Journal of Radiological Review 2022 September;9(3):133-7

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW   

Journal of Radiological Review 2022 September;9(3):133-7

DOI: 10.23736/S2723-9284.22.00190-3

Copyright © 2022 EDIZIONI MINERVA MEDICA

language: English

Is PET/MRI destined to replace PET/CT in oncology imaging?

David A. NISBET , Emanuele NERI, Dania CIONI

Department of Translational Research, University of Pisa, Pisa, Italy



The aim of this study was to try and determine whether PET/MRI hybrid imaging is the natural progression from PET/CT as a cost-effective imaging and treatment modality in oncology imaging. A literature search was conducted using the key words of PET/MRI, PET/CT, hybrid imaging, dose, oncology imaging, head and neck cancer, lung cancer, pelvic cancer, radiopharmaceuticals, theranostics, radiomics and radiogenomics, IAEA. Thirty relevant articles dating from 2009 to 2021 were used for reference and review. For the foreseeable future PET/MRI will most likely be used for very specific imaging needs such as in the pelvis for prostate, rectal and gynecological cancers.


KEY WORDS: Positron emission tomography computed tomography; Magnetic resonance imaging; Multimodal imaging

top of page